Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 2, 2013, Pages 406-412

  Violi, Francesco ^a   Pignatelli, Pasquale ^a   Pignata, Claudio ^b   Plebani, Alessandro ^c   Rossi, Paolo ^d   Sanguigni, Valerio ^d   Carnevale, Roberto ^a   Soresina, Annarosa ^c   Finocchi, Andrea ^d   Cirillo, Emilia ^a   Catasca, Elisa ^b   Angelico, Francesco ^a   Loffredo, Lorenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

atherosclerosis; NADPH oxidase; oxidative stress

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE DERIVATIVE; METHOTREXATE; NITRATE; NITRITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CATALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE; THROMBOCYTOPOIESIS; VASODILATATION;

ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISOPROSTANES; ITALY; LINEAR MODELS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NADPH OXIDASE; NITRATES; NITRITES; OBESITY; OXIDATIVE STRESS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; VASODILATION;

EID: 84872906530     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300438     Document Type: Article

References (44)

1. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109:II27-II33.
2. Ross R. Atherosclerosis-an infammatory disease. N Engl J Med. 1999;340:115-126.
3. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008;5:338-349.
4. Münzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J. 2010;31:2741-2748.
5. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501.
6. Judkins CP, Diep H, Broughton BR, Mast AE, Hooker EU, Miller AA, Selemidis S, Dusting GJ, Sobey CG, Drummond GR. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavail-ability, and early atherosclerotic plaque formation in ApoE-/-mice. Am J Physiol Heart Circ Physiol. 2010;298:H24-H32.
7. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest. 2001;108:1513-1522.
8. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM. NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal. 2006;8:691-728.
9. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, Malech HL, Holland SM, Ochs H, Quie P, Buckley RH, Foster CB, Chanock SJ, Dickler H. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79:155-169.
10. Loffredo L. Chronic granulomatous disease. Intern Emerg Med. 2011;6: 125-128.
11. Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, Uzel G, DeRavin SS, Priel DA, Soule BP, Zarember KA, Malech HL, Holland SM, Gallin JI. Residual NADPH oxidase and survival in chronic granu-lomatous disease. N Engl J Med. 2010;363:2600-2610.
12. Martire B, Rondelli R, Soresina A, et al.; IPINET. Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin Immunol. 2008;126:155-164.
13. Violi F, Sanguigni V, Carnevale R, et al. Hereditary defciency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation. 2009;120:1616-1622.
14. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of fow-mediated dilation to ankle-brachial pressure index. Circulation. 2003;108:2093-2098.
15. Loukogeorgakis SP, van den Berg MJ, Sofat R, Nitsch D, Charakida M, Haiyee B, de Groot E, MacAllister RJ, Kuijpers TW, Deanfeld JE. Role of NADPH oxidase in endothelial ischemia/reperfusion injury in humans. Circulation. 2010;121:2310-2316.
16. Mancini GB, Dahlöf B, Díez J. Surrogate markers for cardiovascular disease: structural markers. Circulation. 2004;109(25 Suppl 1):IV22-IV30.
17. Richardson MP, Ayliffe MJ, Helbert M, Davies EG. A simple fow cytom-etry assay using dihydrorhodamine for the measurement of the neutro-phil respiratory burst in whole blood: comparison with the quantitative nitrobluetetrazolium test. J Immunol Methods. 1998;219:187-193.
18. Mauch L, Lun A, O'Gorman MR, Harris JS, Schulze I, Zychlinsky A, Fuchs T, Oelschlägel U, Brenner S, Kutter D, Rösen-Wolff A, Roesler J. Chronic granulomatous disease (CGD) and complete myeloperoxidase defciency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD. Clin Chem. 2007;53:890-896.
19. Di Matteo G, Giordani L, Finocchi A, et al.; IPINET (Italian Network for Primary Immunodefciencies). Molecular characterization of a large cohort of patients with Chronic Granulomatous Disease and identi-fcation of novel CYBB mutations: an Italian multicenter study. Mol Immunol. 2009;46:1935-1941.
20. Barlow SE; Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120:S164-S192.
21. Martínez-González MA, Fernández-Jarne E, Serrano-Martínez M, Wright M, Gomez-Gracia E. Development of a short dietary intake questionnaire for the quantitative estimation of adherence to a cardioprotec-tive Mediterranean diet. Eur J Clin Nutr. 2004;58:1550-1552.
22. Diagnosis and classifcation of diabetes mellitus. Diabetes Care. 2011;34:S62-69.
23. Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii). JAMA. 2001;285:2486-2497.
24. Pignatelli P, Carnevale R, Di Santo S, Bartimoccia S, Sanguigni V, Lenti L, Finocchi A, Mendolicchio L, Soresina AR, Plebani A, Violi F. Inherited human gp91phox defciency is associated with impaired iso-prostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol. 2011;31:423-434.
25. Hoffman SW, Roof RL, Stein DG. A reliable and sensitive enzyme immunoassay method for measuring 8-isoprostaglandin F2 alpha: a marker for lipid peroxidation after experimental brain injury. J Neurosci Methods. 1996;68:133-136.
26. Wang Z, Ciabattoni G, Créminon C, Lawson J, Fitzgerald GA, Patrono C, Maclouf J. Immunological characterization of urinary 8-epi-prostaglan-din F2 alpha excretion in man. J Pharmacol Exp Ther. 1995;275:94-100.
27. Pignatelli P, Di Santo S, Buchetti B, Sanguigni V, Brunelli A, Violi F. Polyphenols enhance platelet nitric oxide by inhibiting protein kinase C-dependent NADPH oxidase activation: effect on platelet recruitment. FASEB J. 2006;20:1082-1089.
28. Pignatelli P, Carnevale R, Cangemi R, Loffredo L, Sanguigni V, Stefanutti C, Basili S, Violi F. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2010;30:360-367.
29. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfeld J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R; International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-depen-dent fow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265.
30. Loffredo L, Marcoccia A, Pignatelli P, Andreozzi P, Borgia MC, Cangemi R, Chiarotti F, Violi F. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. Eur Heart J. 2007;28:608-612.
31. Praticò D. Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis. 2008;201:8-16.
32. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratifcation for postoperative cardiovascular events via noninva-sive assessment of endothelial function: a prospective study. Circulation. 2002;105:1567-1572.
33. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, Vita JA. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. 2003;41:1769-1775.
34. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial fow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007;115:2390-2397.
35. Charakida M, Masi S, Lüscher TF, Kastelein JJ, Deanfeld JE. Assessment of atherosclerosis: the role of fow-mediated dilatation. Eur Heart J. 2010;31:2854-2861.
36. Oelze M, Warnholtz A, Faulhaber J, Wenzel P, Kleschyov AL, Coldewey M, Hink U, Pongs O, Fleming I, Wassmann S, Meinertz T, Ehmke H, Daiber A, Münzel T. NADPH oxidase accounts for enhanced superoxide production and impaired endothelium-dependent smooth muscle relaxation in BKbeta1-/-mice. Arterioscler Thromb Vasc Biol. 2006;26:1753-1759.
37. Donato AJ, Eskurza I, Silver AE, Levy AS, Pierce GL, Gates PE, Seals DR. Direct evidence of endothelial oxidative stress with aging in humans: relation to impaired endothelium-dependent dilation and upreg-ulation of nuclear factor-kappaB. Circ Res. 2007;100:1659-1666.
38. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Lüscher TF. Nitric oxide is responsible for fow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 1995;91:1314-1319.
39. Heiss C, Lauer T, Dejam A, Kleinbongard P, Hamada S, Rassaf T, Matern S, Feelisch M, Kelm M. Plasma nitroso compounds are decreased in patients with endothelial dysfunction. J Am Coll Cardiol. 2006;47:573-579.
40. Lundberg JO, Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol. 2005;25:915-922.
41. Cale CM, Morton L, Goldblatt D. Cutaneous and other lupus-like symptoms in carriers of X-linked chronic granulomatous disease: incidence and autoimmune serology. Clin Exp Immunol. 2007;148:79-84.
42. McMahon M, Hahn BH, Skaggs BJ. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol. 2011;7:227-241.
43. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459-467.
44. Douglas G, Bendall JK, Crabtree MJ, Tatham AL, Carter EE, Hale AB, Channon KM. Endothelial-specifc Nox2 overexpression increases vascular superoxide and macrophage recruitment in ApoE-/-mice. Cardiovasc Res. 2012;94:20-29.